Apfel T, Lopez R, Sanaka MR, Thota PN. Risk of progression of Barrett's esophagus in patients with cirrhosis. World J Gastroenterol 2017; 23(18): 3287-3294 [PMID: 28566888 DOI: 10.3748/wjg.v23.i18.3287]
Corresponding Author of This Article
Prashanthi N Thota, MD, FACG, Director, Esophageal Center, Department of Gastroenterology and Hepatology, Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, United States. thotap@ccf.org
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
research-article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 14, 2017; 23(18): 3287-3294 Published online May 14, 2017. doi: 10.3748/wjg.v23.i18.3287
Risk of progression of Barrett's esophagus in patients with cirrhosis
Prashanthi N Thota, Madhusudhan R Sanaka, Rocio Lopez, Tehilla Apfel
Tehilla Apfel, Department of General Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, United States
Rocio Lopez, Department of Biostatistics, Cleveland Clinic Foundation, Cleveland, OH 44195, United States
Madhusudhan R Sanaka, Prashanthi N Thota, Department of Gastroenterology and Hepatology, Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, United States
Author contributions: Apfel T collected data, drafting this manuscript; Lopez R statistical analysis; Sanaka MR designed study, revised this manuscript; Thota PN designed and supervised this study, drafting and revised of manuscript.
Institutional review board statement: The study was reviewed and approved for publication by our Institutional Reviewer.
Informed consent statement: Informed consent waived by institutional review board as it is a retrospective case control study.
Conflict-of-interest statement: All the Authors have no conflict of interest related to the manuscript.
Data sharing statement: The original anonymous dataset is available on request from the corresponding author at thotap@ccf.org.
Correspondence to: Prashanthi N Thota, MD, FACG, Director, Esophageal Center, Department of Gastroenterology and Hepatology, Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, United States. thotap@ccf.org
Telephone: +1-216-4440780 Fax: +1-216-445-4222
Received: January 23, 2017 Peer-review started: January 27, 2017 First decision: February 23, 2017 Revised: March 11, 2017 Accepted: April 21, 2017 Article in press: April 21, 2017 Published online: May 14, 2017 Processing time: 112 Days and 0.3 Hours
Core Tip
Core tip: Fifty seven cirrhotic patients with Barrett’s esophagus (BE) were compared to 228 non-cirrhotic BE controls. Nonalcoholic steatohepatitis or cardiac cirrhosis was the most common causes of cirrhosis in this group. There were no differences in incidence rates of high-grade dysplasia (HGD)/esophageal adenocarcinoma (EAC) in nondysplastic BE between cirrhotic cases and noncirrhotic controls (1.4 vs 1.1 per 100 person -years, P = 0.8). In low grade dysplasia, cirrhotic patients were found to have higher rates of progression to HGD/EAC compared to control group though this did not reach statistical significance (13.7 vs 8.1 per 100 person- years, P = 0.51). There was approximately 8 times increased risk of progression for every one point increase in Child- Pugh class.
